Pharma & Bio
Technology
KMPHARMACEUTICAL Co.,Ltd. Rises on ‘Delisting Notice’… SK BIOPHARMACEUTICALS Falls as FDA Puts Decision on Hold [Bio Spotlight]
On the 11th, the pharmaceutical and biotech sector showed strength, with both KMPHARMACEUTICAL Co.,Ltd.(225430)and BL Pharmtech(065170)hitting their daily price limits. Notably, KMPHARMACEUTICAL Co.,L…
- 2026-09-15 08:28:02
- KIM SUNG-JIN
Technology
“Chinese Biotech Firms Follow South Korean Disclosure Practices”… How K-Bio Can Survive Caught Between the U.S. and China [K-Bio Deal Summit]
Lee Seung-kyu, Vice Chairman of the Korea Bio Association; Heo Hye-min, an analyst at Kiwoom Securities; Han Jeong-hyun, Head of BD&L at Boehringer Ingelheim Korea; and Kim Myung-ki, CEO of LSK Invest…
- 2026-09-15 08:02:02
- KIM SAE-MI
Technology
Coreline Soft Co., Ltd., After Six Years of Dedication… Begins Full-Scale Market Push in Japan with Its Own AI for Detecting Lung Nodules
Coreline Soft Co., Ltd.(384470)has secured approval for the manufacture and sale in Japan of its proprietary artificial intelligence (AI) system for detecting pulmonary nodules, following 5 years and …
- 2026-09-14 11:01:02
- NA EUN-KYUNG
Technology
DongBang Medical Co., Ltd. Enters the Toxin Business... Considering Equity Investment in a Strain-Developing Company
Medical device specialist #DongBang Medical Co., Ltd. is considering entering the botulinum toxin business. Having grown by specializing in dermal fillers, cannulas, and various traditional Korean med…
- 2026-09-14 08:21:02
- KIM SUNG-JIN
Lifestyle
“Which of 100,000 AI-Generated New Drugs Are Legitimate?”…PROTEINA CO., LTD. Screens Candidate Compounds Through Large-Scale Experimental Validation
While an era is dawning in which artificial intelligence (AI) can rapidly design tens of thousands or even hundreds of thousands of antibodies, the designs produced by AI do not immediately become new…
- 2026-09-14 08:01:05
- KIM JI-WAN
Lifestyle
TG-C Failed to Clear U.S. Phase 3 Trials… Three Reasons Why Cartistem Is Confident
As Medipost begins full-scale Phase 3 clinical trials in the U.S. for “Cartistem,” a stem cell therapy for knee osteoarthritis, attention is focusing on its potential for success. Despite the clinical…
- 2026-09-14 08:01:04
- Kim Jinsoo
Disclosure Plus
Voronoi, Inc. Offers ‘30 Trillion Won M&A Success Bonus’ to Former Lilly CMO… The Math Behind the Unprecedented Stock Options
Voronoi, Inc.(310210)has granted its Chief Medical Officer (CMO), a former Eli Lilly executive, extraordinary stock options that can only be exercised if a change in control occurs when the company’s …
- 2026-09-14 08:01:03
- KIM SAE-MI
Business·Industry
[Noul Co., Ltd. Deep Seek ④] The Aftermath of an RP Agreement Made During a Rights Offering… 4 Million Shares Held by the Largest Shareholder Transferred to External Parties
MSEED, the largest shareholder of artificial intelligence (AI) diagnostics company Noul Co., Ltd.(376930), is facing repercussions from a repurchase agreement (RP) signed during its participation in a…
- 2026-09-13 08:06:02
- KIM SAE-MI
Business·Industry
DRTECH Surges on Return to Market; HLB Innovation and L&K Biomed Rise [K-bio pulse]
On September 10, DRTECH, which resumed trading following the completion of a reverse stock split, saw sharp swings in its share price. The medical imaging company drew investor attention as expectatio…
- 2026-09-12 08:42:02
- Kim Jinsoo
Lifestyle
DRTECH Corporation Draws Attention as Trading Resumes… HLB INC. and L&K BIOMED CO., LTD. Reflect Market Optimism [Bio Spotlight]
On the 10th, shares of DRTECH Corporation(214680), which resumed trading after completing a stock consolidation, experienced significant volatility in the pharmaceutical and biotech sector. DRTECH Cor…
- 2026-09-12 08:41:02
- Kim Jinsoo
PHARM EDAILY
Shorts